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To maintain its health, an organism must be able to repel
infectious invaders. In animals, phagocytic cells—profes-
sional hunters—are essential to this process. This creates
another level of challenge: how to get the phagocytic cells
to the site(s) where they are needed without activating
them prematurely. Several molecular events are required to
orchestrate this properly. For example, endothelial cells
must display appropriate adhesion proteins to supply the
spatial specificity (1), and the phagocyte must be able to
“smell” and respond to chemical stimuli that direct its acti-
vation and migration. Identification of the scents that at-
tract the hunters and signals from phagocyte to phagocyte
has progressed over the past two decades, and one of the
first endogenous compounds to be chemically characterized
 
was leukotriene B
 
4
 
 (LTB
 
4
 
).
In the first experiments that led to the discovery of leu-
kotrienes, Borgeat et al. (2) reported a novel 5-lipoxygen-
ase, and subsequent analysis of the products of this pathway
led to the structural elucidation of three major compounds
(3, 4), one of which was LTB
 
4
 
. The biological function of
 
LTB
 
4
 
, which is generated by polymorphonuclear leukocytes
(PMNs), was elucidated in experiments by Ford-Hutchin-
son et al. (5). At the time, it was a significant challenge to
separate mono-, di-, and tri-hydroxy eicosatetraenoic acids
(HETEs). This was problematic because several isomers of
5,12-di-HETE were present in the extracts from activated
PMNs, and it was difficult to determine which of them
carried biological activity. Ford-Hutchinson et al. tested
fractions eluted from an HPLC separation and found a sin-
gle major peak of chemoattractant activity. They also re-
ported that this compound, which was subsequently shown
to be LTB
 
4
 
,
 
 
 
was a potent stimulator of chemokinesis and
aggregation. These findings led the field away from a prior
focus on mono-HETE as primary mediator. A battery of
papers that determined the complete structure of LTB
 
4
 
 was
published in this journal in the early 1980s. The first paper
established the complete stereochemistry of LTB
 
4
 
 as 5(S),
12(R)-dihydroxy-eicosa-6,8,10-(trans/trans/cis), 14(cis)-tet-
raenoic acid and showed that it was this isomer alone that
accounted for the proinflammatory activity of LTB
 
4
 
 (6).
The second paper used materials prepared by total organic
synthesis and confirmed that, of the several stereoisomers
present in biological preparations, LTB
 
4 
 
that was the rele-
vant
 
 
 
compound (7). This precise chemical characterization
was important for many reasons, but one of the most pro-
found insights was that the phagocytes were able to distin-
guish between very similar compounds and to respond to
only the one with the “correct” stereochemistry. This im-
plied that there was a specific receptor that could discrimi-
nate between stereoisomers. A series of papers in this issue
addresses the regulation of expression of the LTB
 
4
 
 receptor
that was identified a few years earlier (Kato et al. [8]) and
the role of this receptor in animal models of inflammation
(Haribabu et al. [9] and Tager et al. [10]) and reports a sec-
ond, lower affinity receptor in cells other than leukocytes
(Yokomizu et al. [11]).
The extensive molecular characterization of cell surface
receptors and the mechanisms by which they send signals
into the cell are a remarkable recent advance in biology and
medicine. But the ability of phagocytes and other cells of
inflammation and immunity to respond selectively has been
recognized for many years. As early as 1883, Metchnikoff
presented his hypothesis that leukocytes recognized foreign
microbes and destroyed them using a process of engulfment
or phagocytosis, the term he introduced to describe their
“eating character.” Embodied in his observations was the
concept that leukocytes chemotax in response to chemical
signals, which we now know include LTB
 
4
 
. We also know
that the general structure of receptors and the subsequent
events have been conserved and are the molecular under-
pinnings of our various senses. For example, the large fam-
ily of receptors that detects odorants is a branch of the G
protein–coupled receptor family, just as are the receptors
for LTB
 
4
 
 (12, 13). Such conservation and connections had
been suspected. For example, Thomas (14) was intrigued
by the exquisite ability to distinguish between different
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odorants and postulated that it was in some way related to
the ability to distinguish self from nonself. He and his col-
leagues conducted experiments that showed that blood-
hounds could distinguish between congenic mice that dif-
fered only at the H2 locus, and that the mice themselves
seemed able to make the distinction (14). Thus, the ability
to smell—either by nasal epithelia or phagocytes—influ-
ences our ability to mount appropriate immune and in-
flammatory responses.
The potential for therapeutic uses of inhibitors of leuko-
 
triene generation and/or their function(s) was apparent early
based on the initial descriptions of their putative roles in in-
flammation and a wide range of human diseases and disor-
ders (15). The subsequent discovery and cloning of the re-
ceptor for LTB
 
4
 
 made an attack on this target possible. But
too much antiinflammatory effect would put the organism
at risk of not being able to fight infection or other chal-
lenges. 
Using radiolabeled LTB
 
4
 
 and traditional medicinal chem-
istry, a number of pharmacologically defined receptors were
described, and receptor antagonists were prepared without
having the leukotriene receptor in hand. Although antago-
nists were effective in vitro, there were few clear clinical
indications for when to use them in vivo (16). The discov-
ery and structural characterization of G protein–coupled re-
ceptors (GPCRs; for review see reference 17) opened the
possibility of obtaining the elusive LTB
 
4
 
 receptor. Shimizu’s
laboratory, after the initial description of specific binding
sites for LTB
 
4
 
 by Goetzl et al. (6), tried in what is reported
to be more than a 10-year quest to identify and clone the
LTB
 
4
 
 receptor. In 1997, Yokomizo et al. (18) reported the
identification of a GPCR that recognized LTB
 
4
 
 in a stereo-
selective fashion and evoked chemotaxis when placed in a
reporter cell line to demonstrate in vitro chemotaxis. As a
wide range of closely related structures did not activate this
 
receptor, it was named BLT1. The receptor had been
described earlier but was misidentified as an atypical puri-
nergic receptor by another group that had cloned it as a
member of a set of orphan GPRCs. BLT1 belongs to the
subfamily of GPRCs that includes chemokines and related
chemotactic receptors and is distinct from the subfamily of
prostaglandin receptors (19).
At this stage of the history of LTB
 
4
 
, all of the evidence
pointed to its likely role as a key mediator of inflammation,
but the evidence in vivo was incomplete. The use of ge-
netically altered mice was a leap forward in the evaluation
of the 5-lipoxygenase pathway (20, 21). Results from these
mice provided strong evidence that products of the path-
way play an important role in inflammatory insults; defi-
cient mice had blunted responses to topical arachidonic
acid and increased resistance to platelet-activating factor
(PAF)-induced shock. Also, zymosan-induced peritonitis
was markedly reduced in mice deficient in their ability to
generate leukotrienes, presumably LTB
 
4
 
. Conversely, over-
expression of the receptor in the leukocytes of BLTR-trans-
genic mice enhanced leukocyte responsiveness in acute der-
mal inflammation, their trafficking to remote organs, and
their recruitment to a peritoneal challenge. These results
also led to the conclusion that LTB
 
4
 
 is a culprit in a variety
of circumstances in which inappropriate or excessive acti-
vation leads to leukocyte-mediated injury (22). Of particu-
lar interest, overexpression of the receptor in vivo led to an
unexpected upregulation of 5-lipoxygenase expression and
leukotriene biosynthesis, emphasizing that receptor overex-
pression amplifies proinflammatory circuits in vivo. These
findings reaffirmed the receptor as a logical target for ther-
apy designed to suppress excessive inflammation. But re-
lated work in inflammation over the years had also led to
the identification of additional signals for phagocytes—
PAF, C5a, monocyte chemoattractant protein 1, and oth-
ers—and whether loss of the scent for one of these would
blunt inflammation was in question, as the redundancy
seemed so extensive. Papers in the current series address
this issue.
In the first paper, Kato et al. (8) report studies to define
the regulation of BLT1, focusing on the transcriptional
events that account for its selective expression in leuko-
cytes. They determined the structure of the gene, which is
simple as is typical with GPCR genes, and then identified
the promoter region and transcription start site. They
 
found that the region from the start upstream to 
 
2
 
76,
which contains a binding site for Sp1, was required for ex-
pression. Then, they showed that Sp1 binds to this region
and activates transcription and that mutation of the site
abolishes the response. This defined a key mechanism for
expressing the gene but left the issue of why the expression
is so selective essentially only in leukocytes of myeloid lin-
eage. They went on to answer this question as well. The
sequence around the Sp1 site is rich in CpG sites, and their
experiments showed that there is methylation of such sites
in nonmyeloid cells and that this prevents transcription of
the BLT1 gene. Thus, this series of experiments provided a
detailed mechanism for the selective expression of the
BLT1 receptor. There is great interest in therapeutic ap-
proaches, particularly for cancer, that prevent methylation
of regulatory sequences and activate the transcription of
genes such as tumor suppressors. The work by Kato et al.
(8) suggests that drugs that achieve this goal might also in-
crease the spectrum of cells that express the BLT1 receptor,
which could yield an unexpected set of responses.
In the course of their studies on expression of the BLT1
gene, Yokomizu et al. (11) discovered that an open reading
frame for a second LTB
 
4
 
 receptor, now denoted BLT2, is
embedded in the promoter sequence, a first example of, as
the investigators report, “a promoter and an open reading
frame” in higher eukaryotes. BLT2 is highly similar to
 
BLT1, with amino acid identity of 
 
z
 
45%, but the protein
is a low affinity receptor for LTB
 
4
 
: the K
 
d
 
 value is 23 nM,
compared with 1 nM for BLT1. BLT2, unlike BLT1, is
expressed ubiquitously, and when expressed in CHO cells,
the cells chemotax and mobilize calcium in a pertussis
toxin–sensitive fashion in response to LTB
 
4
 
. Thus, the sig-
naling initiated by LTB
 
4 
 
binding to the two receptors ap-
pears to be very similar except for their differences in affin-
ity for the ligand. The role of BLT2 in responses associated
with LTB
 
4
 
 is not known but intriguing. For example, since 
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LTB
 
4
 
 is a signaling molecule between leukocytes, promot-
ing cell–cell communication, the presence of receptors of
different affinity may somehow participate in innate immu-
nity. Furthermore, this new receptor, BLT2, may be the
key to understanding the role, if any, of LTB
 
4
 
 in processes
other than host defense. If it serves an independent func-
tion, BLT2 could be a target for pharmacological interven-
tion if selective antagonists can be developed.
The focus of the other two papers in this series (9, 10) is
the physiological and pathological roles of the BLT1, and
both tackled the problem with the same approach, targeted
gene disruption. In both reports, leukocytes from the
knockout animals showed a loss of responsiveness to LTB
 
4
 
as expected when studied in vitro, but, importantly, the
cells remained responsive to other proinflammatory ago-
nists, a circumstance that would allow the test of the im-
portance of LTB
 
4
 
 sensing in vivo in models of inflamma-
tion. Both Haribabu et al. (9) and Tager et al. (10) found
that peritoneal inflammation was suppressed in the defi-
cient mice; interestingly, they described different time-
dependent patterns: Haribabu et al. documented a loss of
protection over 72 h, whereas Tager et al. observed in-
creasing protection with time. In addition, Tager et al.
found that a dramatic diminution in the number of eosino-
phils accounted for virtually all of the changes in cellular
influx, while Haribabu et al. noted decrements in both
PMNs and macrophages. The basis for these differences is
not clear, but they may be the result of different provoca-
tions for the inflammation (zymosan versus thioglycollate).
Tager et al. also documented that the adhesion of BLT1
 
2
 
/
 
2
 
leukocytes to endothelium, as expected, was diminished in
response to LTB
 
4
 
, findings that are in line with earlier ob-
servations with LTB
 
4
 
 in vital microscopy using the hamster
cheek pouch (23). Interestingly, Haribabu et al. (9) ob-
served that female but not male knockout mice were
highly resistant to PAF-induced anaphylaxis. It is essential
to reemphasize that the cells in vitro responded to PAF
and, thus, these experiments give strong support to the pre-
vious evidence that the effects of PAF in vivo largely de-
pend on downstream generation of LTB
 
4
 
 and its subse-
quent actions. The LTB
 
4
 
 signaling cascade seems to be a
common downstream pathway in these experimental set-
tings and therefore an attractive target for pharmacological
regulation in, acute inflammatory disorders.
What does the future hold, in view of these findings? It
is clear that having a second receptor for LTB
 
4
 
 as well as a
high affinity receptor will permit the total organic synthesis
and development of highly selective agonists and antago-
nists that should find their way to the clinic, perhaps ini-
tially in the treatment of acute, rapid onset events of patho-
genesis such as adult respiratory distress syndrome or
second organ reperfusion injury where neutrophil infiltra-
tion is a primary player that leads to organ failure (22). The
availability of knockouts for the receptor will permit testing
the selectivity of such receptor antagonists as well as explo-
ration of other potential roles and mechanisms of action for
LTB
 
4
 
 itself. It will be interesting to see if these mice de-
velop compensatory mechanisms along the lines of upregu-
 
lation of the 5-lipoxygenase pathway, observed in mice
overexpressing BLT1 (22), and how these receptor levels
may be altered in disease models and during treatment with
a specific leukotriene antagonist and/or selective cyclooxy-
genase-1,2 inhibitors (as in reference 24). Also, what is the
basis for the unexpected gender-specific effects in PAF-
induced shock? Could BLT2 be involved here, or are there
other ways for PAF to work its mischief? Will manipula-
tions of gene methylation with the intention of other ther-
apeutic goals result in abnormal expression of BLT1 in tis-
sues where it normally is suppressed? If so, what will the
consequences be: Can a scent for inflammation smell not as
sweet in a different context?
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